ADC Therapeutics SA (ADCT) Earnings Call Analysis

NYSE · Healthcare · Biotechnology

Earnings Reports

• ADC Therapeutics (ADCT) Q1 2026: Operating Expenses Down 13% as Zynlanta Awaits Key Lotus 5 Readout
  May 04, 2026
• ADC Therapeutics (ADCT) Q4 2025: Operating Expenses Down 15% as Pipeline Focus Sharpens Ahead of Lotus 5 Data
  March 10, 2026
• ADC Therapeutics (ADCT) Q3 2025: $60M Capital Infusion Extends Runway as Zynlonta Combo Trials Accelerate
  November 10, 2025
• ADC Therapeutics (ADCT) Q2 2025: Lotus 7 Delivers 87% Complete Response Rate, Reshaping DLBCL Market Path
  August 12, 2025
• ADC Therapeutics (ADCT) Q1 2025: Lotus 7 Response Rate Hits 95.5%, Accelerating Compendia Path
  July 03, 2025
• ADC Therapeutics (ADCT) Q3 2024: Zynlonta Revenue Rises 26% as Pipeline Focus Shifts to Hematology
  November 07, 2024
• ADC Therapeutics (ADCT) Q2 2024: Operating Expenses Down 23% as Commercial Profitability Reached and Pipeline Advances
  August 06, 2024
• ADC Therapeutics (ADCT) Q1 2024: $105M Financing Extends Runway as Zynlonta Pipeline Expands
  May 06, 2024
• ADC Therapeutics (ADCT) Q4 2023: Zynlonta Net Revenue Climbs 17% as Pipeline Refocuses on Hematology and Next-Gen ADCs
  March 13, 2024

Browse all companies